Alector, AL001-3

I'm Interested!

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of AL001 in Individuals at Risk for or With Frontotemporal Dementia Due to Heterozygous Mutations in the Progranulin Gene

Sex at Birth: Any
Age: Adult (18 - 64), Older Adult (65+)
Accepting Healthy People: No
Type: Interventional / Therapeutic
Trial Phase: Phase III
Conditions Being Studied: Brain and Nervous System, Dementia

Study Purpose

This study will test an experimental drug called AL001 for the treatment of individuals who have a progranulin gene mutation that causes frontotemporal dementia (FTD). An experimental drug is a drug, or a form of a drug, that is not yet approved by regulatory authorities.

Principal Investigator
Brian Appleby MD

Department/Division
Brain Health and Memory (Neurology)

Locations

UH Cleveland Medical Center
11100 Euclid Avenue
Cleveland OH, 44106

Get Directions

UH IRB: SITE00001197
StudyID: 2020-0182
ClinicalTrials.gov: NCT04374136

I'm Interested!

Fill out our online form

Questions or concerns? We're here to help.

Non-cancer Trials: 1-833-78TRIAL or Contact Us Online

Cancer Trials: 1-800-641-2422